U.K. Regulator Suspends Use of Amgen's Avacopan Due to Data Concerns
The Medicines and Healthcare Products Regulatory Agency in the United Kingdom has suspended the use of Amgen’s (AMGN) rare-disorder therapy, Avacopan Vifor (formerly Tavneos), due to concerns over insufficient data supporting its approval. The decision raises questions about the drug's safety or efficacy profile as evaluated by U.K. regulators. Amgen is a major biotechnology firm with significant exposure in global markets for innovative therapies. This regulatory action could affect Amgen’s market strategy and revenue projections, particularly if similar actions are taken elsewhere.
Tickers: $AMGN
Topics: Amgen pharmaceuticals regulation